甲磺酸贝舒地尔片不同版本一盒的最新价格公布

Introduction: Besudil mesylate tablets are an innovative treatment method designed to restore immune homeostasis and down-regulate the fibrotic process of cGVHD. Besudil mesylate is indicated for the treatment of chronic graft-versus-host disease in adults and children at least 12 years of age after at least two other treatments have failed.

The latest prices for a box of different versions of Besudil Mesylate Tablets are announced

Currently, we know that the original drug has been launched in China and has been included in medical insurance. The winning bid price under medical insurance is about $20,418 per box. The price after medical insurance reimbursement will be cheaper. The reimbursement ratio is different in each region, and the specific price after reimbursement is also different. The actual price shall prevail.

The price of the generic version of Besudil Mesylate Tablets produced by Lucius is about 4050$-4800$ per box, which may change due to factors such as market demand and purchasing channels. Patients are advised to refer to the actual purchase price.

After purchasing Besudil Mesylate Tablets, you need to take the medicine under the guidance of a doctor and understand the drug usage, contraindications, precautions, etc.

Dosage and usage of Besudil mesylate tablets

1. Common adult dosage for the treatment of graft-versus-host disease: The recommended dose is 200 mg, taken once a day, and needs to be taken continuously until chronic graft-versus-host disease (GVHD) progresses to the point where new systemic treatment is required.

2. Common pediatric dosage for the treatment of graft-versus-host disease: The dosage for children under 12-18 years old is 200 mg, taken once a day, and continued treatment until chronic graft-versus-host disease (GVHD) progresses to the point where new systemic therapy is required.

Drug interactions of Besudil mesylate tablets

1. Strong CYP3A inducers: Combining Besudil mesylate tablets with strong CYP3A inducers will reduce the exposure of Besudil mesylate tablets, which may reduce the efficacy of Besudil mesylate tablets. When used concomitantly with strong CYP3A inducers, the dose of besudil mesylate tablets should be increased to 200 mg twice daily.

2. Proton pump inhibitors: The combination of Besudil mesylate tablets and proton pump inhibitors will reduce the exposure of Besudil mesylate tablets, which may reduce its efficacy. When used concomitantly with a proton pump inhibitor, the dose of besudil mesylate tablets should be increased to 200 mg twice daily.

According to the results of animal experiments and its mechanism of action, besudil mesylate tablets may cause harm to the fetus when taken by pregnant women. Pregnant women are advised to be aware of potential risks to the fetus. It is recommended that women of childbearing potential and men with female partners of childbearing potential use effective contraceptive measures during treatment with besudil mesilate tablets and for one week after the last dose.